Chronic Coronary Syndrome Clinical Trial
— TITAN-DEBOfficial title:
TicIn for the Treatment of coronAry lesioNs With Drug Eluting Balloons
The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions. Participants with chronic coronary disease and long coronary stenosis will be randomly assign to be treated either with Magic Touch balloon or drug eluting stent.
Status | Recruiting |
Enrollment | 130 |
Est. completion date | December 1, 2030 |
Est. primary completion date | June 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult patients (=18 years old) with chronic coronary syndrome deemed suitable for PCI 2. At least one significant de-novo coronary lesion (defined as diameter stenosis > 50% on angiography, with flow limiting features, confirmed with FFR =0.80 or iFR =0.89 and intended implantation of a long (=30 mm) DES based on IVUS findings 3. Written informed consent Exclusion Criteria: 1. Patients referred to the index procedure for an acute coronary syndrome 2. Target lesion involving the left main and/or ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery 3. Severe renal impairment (eGFR<15ml/min/1.73m2) or patient on dialysis treatment 4. Spontaneous coronary artery dissection (SCAD) 5. Contraindications to adenosine administration (e.g. moderate to severe asthma or chronic obstructive pulmonary disease, heart rate <50 beats/min and systolic blood pressure <90 mmHg) 6. Known pregnancy or breast-feeding patients 7. Life expectancy <1 year due to other severe non-cardiac disease 8. Legally incompetent to provide informed consent 9. Participation in another clinical study with an investigational product |
Country | Name | City | State |
---|---|---|---|
Switzerland | Marco Valgimigli | Lugano |
Lead Sponsor | Collaborator |
---|---|
Cardiocentro Ticino | University of Bern |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Absolute change of FFR values (?FFR) | Absolute change of fractional flow reserve (FFR) values (?FFR) measured at the final assessment immediately after the index PCI and invasive follow-up at 6(±30days) or 12(±30 days) months | At 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | QCA parameter (minimal lumen diameter, MLD, mm) before and after the intervention and at follow-up angiography | Minimal lumen diameter (MLD,mm) before the intervention, immediately after the intervention and at follow-up angiography. | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | QCA parameter (maximal diameter stenosis, MaxS, percent) before and after the intervention and at follow-up angiography | Maximal diameter stenosis (MaxS, percent) before the intervention, immediately after the intervention and at follow-up angiography. | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | QCA parameter (reference vessel diameter, RVD, mm) before and after the intervention and at follow-up angiography | Reference vessel diameter (RVD, mm) before the intervention, immediately after the intervention and at follow-up angiography. | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | QCA parameter (lesion length, LL, mm) before and after the intervention and at follow-up angiography. | Lesion length (LL, mm) before the intervention, immediately after the intervention and at follow-up angiography. | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | QFR parameters before and after intervention and at follow-up angiography | Quantitative Flow Ratio (QFR) parameters before the intervention, immediately after the intervention and at follow-up angiography | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | FFR parameters before and after intervention and at follow-up angiography | Fractional Flow Reserve (FFR) parameters before the intervention, immediately after the intervention and at follow-up angiography | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Minimal lumen diameter (MLD, mm) | Minimal lumen diameter (MLD, mm) evaluated with intravascular ultrasound (IVUS) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Minimal luminal area (MLA, mm^2) | Minimal luminal area (MLA, mm^2) evaluated with intravascular ultrasound (IVUS) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Maximal diameter stenosis (MaxS, percent) | Maximal diameter stenosis (MaxS, percent) evaluated with intravascular ultrasound (IVUS) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Lumen volume (LV, mm^3) | Lumen volume (LV, mm^3) evaluated with intravascular ultrasound (IVUS) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Vessel volume (VV, mm^3) | Vessel volume (VV, mm^3) evaluated with intravascular ultrasound (IVUS) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Plaque burden (VV-LV) | Plaque burden (VV-LV) evaluated with intravascular ultrasound (IVUS) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Late lumen loss (LLL) | Late lumen loss (LLL) evaluated with intravascular ultrasound (IVUS) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Acute gain | Variation between pre treatment (T0) and immediately after the treatment (Tf) | pre procedure and immediately after the procedure | |
Secondary | Disease progression after index PCI | Variation between final result of index PCI (Tf) and procedure at 6(±30days) or 12(±30 days) months after the index PCI (Tc) | pre procedure, immediately after the procedure and at 6(±30days) or 12(±30 days) months after the index PCI | |
Secondary | Target lesion revascularization (TLR) defined as urgent and non-urgent | Rate of target lesion revascularization (TLR) defined as urgent and non-urgent | 5 years after the index PCI | |
Secondary | Target vessel revascularization (TVR), defined as urgent and non-urgent | Rate of target vessel revascularization (TVR), defined as urgent and non-urgent | 5 years after the index PCI | |
Secondary | Target vessel failure (TVF), defined as cardiac death, target-vessel myocardial infarction, and any target lesion revascularization | Rate of target vessel failure (TVF), defined as cardiac death, target-vessel myocardial infarction, and any target lesion revascularization | 5 years after the index PCI | |
Secondary | The individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization) | Rate of the individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization) | 5 years after the index PCI | |
Secondary | Any myocardial infarction | Rate of any myocardial infarction | 5 years after the index PCI | |
Secondary | Stroke | Rate of stroke | 5 years after the index PCI | |
Secondary | Definite or probable stent thrombosis | Rate of definite or probable stent thrombosis | 5 years after the index PCI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06185530 -
SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints
|
N/A | |
Recruiting |
NCT05117866 -
Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study
|
N/A | |
Recruiting |
NCT05727982 -
Identification of Molecular Mechanisms of Coronary Instability in Homogeneous Subsets of Patients With Acute Coronary Syndromes for the Implementation of Precision Medicine
|
||
Completed |
NCT06464276 -
Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study
|
||
Recruiting |
NCT03936504 -
Efficacy and Mechanism of TCCRP in Patients With Chronic Coronary Syndrome Under Fusion Cardiac Rehabilitation Model
|
N/A | |
Recruiting |
NCT05978089 -
Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome(MET STUDY)
|
Phase 4 | |
Recruiting |
NCT05875311 -
Telemonitoring System for Improving Continuity of Care in Patients With Chronic Coronary Syndrome (TELSINCORC)
|
N/A | |
Recruiting |
NCT05865600 -
Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome
|
N/A | |
Recruiting |
NCT06337461 -
Computational mOdelliNg of myoCardial pERfusion to Improve ouTcome Prediction Based on cOronary Artery Stenosis and Atherosclerotic Plaque Burden Assessment by Computed Tomography
|
||
Recruiting |
NCT05640752 -
Optimal Evaluation to Reduce Imaging Testing
|
N/A | |
Recruiting |
NCT05635994 -
Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO)
|
||
Recruiting |
NCT05583786 -
Intracoronary ECG ST-segment Shift Remission Time During Reactive Coronary Hyperemia
|
||
Completed |
NCT05592535 -
Outcomes With Fractional Flow Reserve in Chronic Coronary Syndrome
|
||
Recruiting |
NCT06255678 -
Angio-based Final Functional Effect of PCI
|
||
Recruiting |
NCT06275399 -
Comprehensive Assessment of Morphometric, Functional, Biomechanical and Biological Interactions Between Atherosclerotic Plaque and Platelets Within the Stenosed Coronary Artery
|
||
Not yet recruiting |
NCT06186336 -
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
|
||
Withdrawn |
NCT04738344 -
Very Long Versus Overlapping Stents in Long Coronary Lesions
|
N/A | |
Active, not recruiting |
NCT04135989 -
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
|
Phase 4 | |
Recruiting |
NCT06171061 -
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
|
Phase 4 | |
Recruiting |
NCT05379608 -
Intermittent Hypoxic-hyperoxic Training in Patients With Cardiovascular Pathology After COVID-19 Infection.
|
N/A |